新型苯酞酰亚胺类似物DAID对 Corneal Neovascularization 和视网膜血管渗漏的治疗作用
本研究在体外和氧诱导视网膜病变(OIR)、链脲佐菌素(STZ)糖尿病大鼠模型中评估新型苯酞酰亚胺类似物的抗血管生成作用,发现DAID在体外抑制内皮细胞增殖和VEGF表达,在体内以剂量依赖方式减少视网膜血管渗漏并抑制碱烧伤诱导的角膜新生血管,且玻璃体腔注射未检测到副作用。
要点
- 沙利度胺和三种新型类似物在体外均抑制内皮细胞增殖和VEGF表达。
- DAID在OIR和STZ糖尿病模型中剂量依赖性地减少视网膜血管渗漏。
- DAID局部给药抑制碱烧伤诱导的角膜新生血管。
核心结论
- DAID是一种新型苯酞酰亚胺类似物,通过下调VEGF和炎症因子对新生血管和视网膜血管渗漏发挥强效作用,具有治疗潜力。
研究设计与样本
- 体外采用VEGF ELISA和内皮细胞增殖实验评估新型苯酞酰亚胺类似物的抗血管生成活性。
- 体内采用OIR和STZ诱导糖尿病大鼠模型评估视网膜血管渗漏,采用碱烧伤诱导角膜新生血管模型局部给药评估抗血管生成活性。
- 采用ELISA检测VEGF和ICAM-1表达。
主要发现
- 沙利度胺和三种新型类似物在体外均显示对内皮细胞增殖和VEGF表达的抑制作用。
- 通过玻璃体腔注射,所有化合物均减少OIR和STZ诱导糖尿病模型中的视网膜血管渗漏。
- DAID在OIR和STZ糖尿病模型中均以剂量依赖方式减少视网膜血管渗漏,显示最强效力。
- DAID局部给药抑制碱烧伤诱导的角膜新生血管。
- DAID减弱OIR模型视网膜中VEGF和ICAM-1的过表达。
关键数值与推荐
- 玻璃体腔注射DAID后,视网膜电图和视网膜组织学分析未显示任何可检测的副作用。
临床怎么用
- 原文未报告临床实践建议。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Neovascularization (NV) and retinal vascular leakage are major causes of impaired vision in ocular diseases. The purpose of this study was to identify novel phenylphthalimide analogs with therapeutic effects on NV and vascular leakage and to explore the mechanism of action. METHODS: Antiangiogenic activities of novel phenylphthalimide analogs were assessed in vitro by using VEGF ELISA and endothelial cell proliferation assay. Their efficacies on retinal vascular leakage were evaluated using rat models of oxygen-induced retinopathy (OIR) and streptozotocin (STZ)-induced diabetes. The in vivo antiangiogenic activity was evaluated using topical administration in the alkali burn-induced corneal NV model. The expression of VEGF and intercellular adhesion molecule-1 (ICAM-1) were measured using ELISA. RESULTS: Thalidomide and three novel analogs all showed inhibitory effects on endothelial cell proliferation and VEGF expression in vitro. Through intravitreal injection, all of the compounds reduced retinal vascular leakage in the OIR and STZ-induced diabetic models. Among these compounds, (2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione (DAID) displayed the most potent efficacy and reduced retinal vascular leakage in a dose-dependent manner in both the OIR and STZ-diabetes models. Topical administration of DAID also inhibited alkali burn-induced corneal NV. Furthermore, DAID attenuated the overexpression of VEGF and ICAM-1 in the retina of the OIR model. Intravitreal injection of DAID did not result in any detectable side effects, as shown by electroretinogram and retinal histological analysis. CONCLUSIONS: DAID is a novel phenylphthalimide analog with potent effects on NV and retinal vascular leakage through downregulation of VEGF and inflammatory factors and has therapeutic potential.
引用
- Wang B, Li PK, Ma JX, et al. Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage. Invest Ophthalmol Vis Sci. 2018. PMID: 30029250. doi:10.1167/iovs.18-24015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。